1.
Emerg Infect Dis
; 29(11): 2353-2357, 2023 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37796277
RESUMO
We assessed tecovirimat treatment equity for 3,740 mpox patients in New York, New York, USA, during the 2022 mpox emergency; 32.4% received tecovirimat. Treatment rates by race/ethnicity were 38.8% (White), 31.3% (Black/African American), 31.0% (Hispanic/Latino), and 30.1% (Asian/Pacific Islander/other). Future public health emergency responses must prioritize institutional and structural racism mitigation.